Solentim Cell Metric and VIPS selected by US Government Lab to support latest vaccine research
As part of the concerted fight against COVID-19, the Vaccine Research Center (VRC) at the National Institute for Allergy and Infectious Diseases at the U.S. National Institutes of Health has invested in two key technology platforms from Solentim: the VIPS™ (Verified In-Situ Plate Seeding) high efficiency single cell seeder, and the Cell Metric® high contrast whole well imager. Together, these systems provide and record evidence of clonality, an essential step in quality assurance for cell line development workflows. The instruments will be used to create cell lines to express viral targets under examination for vaccine development.
The VIPS and Cell Metric have been ordered by the Vaccine Production Program (VPP), a division of the VRC responsible for advancing vaccine candidates into treatments to be administered to patients in clinical trials. Solentim’s instruments will enable the VPP to evidence clonal derivation to the FDA for both its antibody and vaccine development workflows.
“We’re delighted to contribute towards the search for a successful COVID-19 vaccine”, says Dr Mark Truesdale, CEO, Solentim. “The VIPS, in conjunction with Cell Metric, provides a rapid and well-established methodology for recording evidence of clonality for cell line workflows.”
Solentim continues to develop workflows for viral-producing cell lines for vaccine research and gene therapy.Please get in touch to find out how Solentim can help you accelerate the development of your Master Cell Banks and ensure you are confidently prepared for regulatory review.